ArticleFrontiers in immunology2026
Combined Lingzhi Huang capsules and Zeng Jian health tonic accelerates skin wound healing via BMP5-mediated inhibition of ferroptosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lingzhi Huang capsules (LZH) and Zeng Jian Health Tonic (ZJ) are traditional Chinese medicinal formulations enriched in polysaccharides and antioxidant components. They have been traditionally used to enhance immunity function and reduce inflammation, promote tissue repair. However, their therapeutic efficacy and underlying mechanisms in skin wound healing have not been fully elucidated. Guided by the Traditional Chinese Medicine principle of "treating the same disease with different therapeutic strategies," this study aimed to evaluate the effects of LZH and ZJ, administered individually and in combination, on skin wound healing and to elucidate the associated molecular mechanisms. Methods: The chemical constituents of LZH and ZJ were characterized using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A full-thickness skin wound model in mice was employed to assess therapeutic effects through histopathological analysis, immunofluorescence, Western blotting, and protein antibody array analysis. In vitro, human umbilical vein endothelial cells (HUVECs) were used to investigate angiogenesis, inflammation, oxidative stress, and ferroptosis. Network pharmacology integrated with protein array profiling was applied to identify key targets and signaling pathways involved in the combined treatment, which were subsequently validated through mechanistic experiments. Results: LZH and ZJ significantly accelerated wound closure, enhanced collagen deposition, and promoted angiogenesis, with the combined treatment exhibiting the most pronounced effects. In HUVECs, LZH + ZJ markedly enhanced cell proliferation, migration, and tube formation; increased CD31 and VEGF expression; reduced reactive oxygen species (ROS) levels; elevated SOD and GSH; decreased MDA levels, and alleviated mitochondrial damage. These effects were accompanied by upregulation of GPX4, SLC7A11, and FTH1. Integrated network pharmacology and protein array analyses revealed enrichment of pathways associated with angiogenesis, inflammation, and ferroptosis, and identified BMP5 as a central regulatory target. Mechanistic validation demonstrated that BMP5 overexpression recapitulated the anti-ferroptotic effects of LZH + ZJ, whereas BMP5 knockdown abolished these protective effects. Conclusion: Combined administration of LZH and ZJ promotes skin wound healing more effectively than either treatment alone by suppressing ferroptosis, inflammation, and oxidative stress through BMP5-mediated signaling. These findings provide mechanistic support for the traditional therapeutic rational and suggest a promising strategy for enhancing wound healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.